|
Home » Briefs » King Drug Company of Florence, Inc. v. Cephalon, Inc.

Services

Econ One’s expert economists have experience across a wide variety of services including antitrust, class certification, damages, financial markets and securities, intellectual property, international arbitration, labor and employment, and valuation and financial analysis.

Resources

Econ One’s resources including blogs, cases, news, and more provide a collection of materials from Econ One’s experts.

Cases and Engagements

Get an Inside look at Economics with the experts.
Managing Director
Education

Ph.D. in Economics, University of California, Los Angeles

M.A. in Economics, University of California, Los Angeles

B.S. in Economics, Santa Clara University

Econ One, President, 1997 – Present

Founded Econ One, 1997

Micronomics, Inc., President and CEO, 1994 – 1997

Micronomics, Inc., Executive Vice President, 1988 – 1997

Cofounded Micronomics, Inc., 1988

National Economic Research Associates, Inc. (Last position was Senior Vice President and member of the Board of Directors) 1980 – 1988

U.S. District Court

U.S. Bankruptcy Court

State Court

Federal Energy Regulatory Commission

Various state tax and regulatory commissions

Private arbitration

International Arbitration

Share this Article
September 25, 2015

King Drug Company of Florence, Inc. v. Cephalon, Inc.

Econ One was retained by counsel for the plaintiffs in the case King Drug Company of Florence, Inc. v. Cephalon, Inc. The plaintiffs are a class of direct purchasers of the brand name prescription drug Provigil, a narcolepsy treatment. They allege that the defendants violated antitrust laws by improperly delaying the market entry of cheaper generic substitutes to Provigil.

Econ One expert Dr. Jeffrey Leitzinger submitted three expert reports and provided deposition testimony on two separate occasions relating to class certification and merits issues. Those issues included the likely impact of a delay in generic competition on the class members, the availability of common, class-wide economic evidence and methodologies that would demonstrate class-wide impact in the form of overcharges, whether those overcharges could be calculated as a whole on an aggregate basis using reliable methodologies, monopoly power and market definition, and aggregate overcharge damages. The class has been certified.

Industries: Pharmaceutical

Latest Related Resources and Insights